Step 1 topics → Musculoskeletal, Skin, and Connective Tissue → Gout Pharmacology

Gout Pharmacology

USMLE Step 1 trap: Initiates allopurinol during an acute gout flare, when it should be deferred until the attack resolves. Allopurinol should not be initiated during an acute gout attack because rapid urate fluctuations can prolong or worsen the flare; it is started after the acute attack resolves.

Gout pharmacology is one of the highest-yield drug categories on USMLE Step 1 because it tests both mechanism and clinical decision-making simultaneously. You need to know not just what each drug does, but when to use it, when to avoid it, and what goes wrong if you pick the wrong one. The drugs fall into two categories: urate-lowering agents (allopurinol, febuxostat, probenecid, pegloticase) and anti-inflammatory agents (colchicine, NSAIDs, steroids) — and the exam loves to blur the line between them to trap you.

USMLE Step 1 tests this topic from multiple angles. Mechanism questions ask you to match a drug to its molecular target or explain why a drug interaction occurs (allopurinol + azathioprine is a classic). Clinical application questions give you a patient scenario — renal failure, kidney stones, G6PD deficiency — and ask which drug is appropriate or contraindicated. Passage-based questions may describe a patient on chemotherapy who develops gout and ask you to reason through the pharmacology. The traps are everywhere: timing of allopurinol initiation, probenecid contraindications, and colchicine's actual mechanism are three of the most commonly missed points.

The biggest conceptual mistake students make is thinking all gout drugs work the same way — reducing uric acid. Colchicine does not lower uric acid at all. Probenecid raises urinary uric acid, which creates its own problems. And allopurinol started during an acute attack doesn't help — it actually makes things worse by destabilizing existing urate deposits. Getting these distinctions right is what separates a passing score from a strong one on USMLE Step 1.

From real student decks
86%have cards covering this topic
78%have mature cards
1.0median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Allopurinol should be started immediately during an acute gout flare to treat the attack.
Right: Allopurinol should not be initiated during an acute gout attack because rapid urate fluctuations can prolong or worsen the flare; it is started after the acute attack resolves.
Starting allopurinol during an acute gout attack is a high-yield trap. Rapid changes in serum urate — whether up or down — destabilize existing monosodium urate crystal deposits and can mobilize new crystals into joints, prolonging or worsening the inflammatory attack. Allopurinol is strictly a maintenance/prophylactic agent; it should only be started after the acute flare has fully resolved, typically with anti-inflammatory cover (colchicine or NSAIDs) for the first few months.
Common mistake
Wrong: Probenecid is appropriate for patients with uric acid kidney stones.
Right: Probenecid increases urinary uric acid excretion and is contraindicated in patients with uric acid nephrolithiasis or renal insufficiency; allopurinol is preferred in these patients.
Probenecid works by blocking urate reabsorption in the proximal tubule, which means uric acid gets dumped into the urine in higher concentrations. In a patient who already forms uric acid kidney stones, this dramatically increases stone risk — you're essentially flooding the urinary tract with the substance that's already causing stones. For these patients (and those with renal insufficiency, where the drug doesn't work well anyway), allopurinol is the correct choice because it reduces total uric acid production rather than shifting it to the kidneys.
Common mistake
Wrong: Colchicine treats gout by inhibiting xanthine oxidase or reducing uric acid levels.
Right: Colchicine treats gout by binding tubulin and inhibiting microtubule polymerization, thereby impairing neutrophil migration and phagocytosis of urate crystals.
Colchicine has nothing to do with xanthine oxidase or uric acid levels — conflating it with allopurinol is a common and punishing error. Colchicine binds tubulin dimers and prevents their polymerization into microtubules, which neutrophils depend on for migration and phagocytosis. By blunting the neutrophil response to urate crystals, colchicine reduces inflammation without touching urate concentrations at all. Think of it as treating the fire (inflammation), not the fuel (uric acid).
Common mistake
Gap: Misses the need to screen for G6PD deficiency before initiating pegloticase due to hemolysis risk
Pegloticase converts urate to allantoin but generates hydrogen peroxide as a byproduct, which can cause hemolytic anemia in G6PD-deficient patients, so G6PD status must be checked before use.
Pegloticase uses uricase (absent in humans) to break down uric acid into allantoin, which is more water-soluble and easily excreted. The catch: this reaction also produces hydrogen peroxide. Normally, G6PD-generated NADPH neutralizes H2O2 in red blood cells via glutathione peroxidase. In G6PD-deficient patients, this defense fails, H2O2 accumulates, oxidizes hemoglobin, and causes hemolytic anemia. Always check G6PD status before starting pegloticase — missing this step is a classic Step 1 clinical reasoning failure.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Allopurinol and febuxostat both inhibit xanthine oxidase — know that this blocks the conversion of hypoxanthine and xanthine to uric acid, and understand why this creates a dangerous interaction with azathioprine and 6-mercaptopurine (which are also metabolized by xanthine oxidase, so their levels skyrocket).
  2. Probenecid is a uricosuric agent that blocks urate reabsorption in the proximal tubule (inhibits URAT1) — know that it increases urinary uric acid, making it contraindicated in patients with uric acid kidney stones or significant renal insufficiency.
  3. Colchicine works by binding free tubulin and inhibiting microtubule polymerization, which impairs neutrophil chemotaxis and phagocytosis of urate crystals — its mechanism is purely anti-inflammatory, not urate-lowering, and its toxicity profile includes diarrhea, nausea, and myopathy.
  4. Pegloticase is a pegylated recombinant uricase that converts uric acid to allantoin — it is reserved for refractory gout, generates hydrogen peroxide as a byproduct, and requires screening for G6PD deficiency before use because H2O2 accumulation triggers hemolytic anemia in G6PD-deficient patients.

Can you avoid these mistakes?

A 58-year-old man with gout and chronic kidney disease (GFR 25) asks about starting a urate-lowering agent. His last 24-hour urine showed high urinary uric acid excretion. Which agent is most appropriate, and why is the alternative contraindicated?
A patient with tophaceous gout is started on allopurinol. Two weeks later he presents with a painful, swollen first MTP joint — worse than before. What went wrong, and what should the management strategy have been?
A physician prescribes colchicine for an acute gout flare. The patient asks how it lowers his uric acid. How do you explain the actual mechanism, and how does it differ from allopurinol?
A patient with refractory gout and normal renal function is started on pegloticase. What lab must be checked before starting, what is the biochemical reason for the risk, and what adverse event are you trying to prevent?

Related topics

Gout Bone Cells and Matrix Endochondral vs Membranous Ossification Fracture Healing Stages Compartment Syndrome

See how your Anki deck covers this topic.

Upload your deck for a free audit →